PHILADELPHIA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two posters for presentation highlighting its development program for Pompe disease at the 26th International Annual Congress of the World Muscle Society (WMS) being held virtually, September 20-24, 2021.
- Cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease: PROPEL study subgroup analyses
- Presenter: Mark Roberts, MD, Consultant Neurologist, Salford Royal NHS Foundation Trust, Greater Manchester Neurosciences Centre, United Kingdom (ePoster #196)
- Living with late-onset Pompe disease in the UK: interim results characterising the patient journey and burden on physical, emotional and social quality of life
- Presenter: Allan Muir, Chair of the Board of Trustees, Pompe Support Network, United Kingdom (ePoster #201)
Cipaglucosidase alfa/miglustat is an investigational therapy that is not yet approved by any regulatory agency.
The posters will be made available on the Amicus website following their respective presentations at the congress.
For more information on the 26th International Annual Congress of the World Muscle Society, please visit www.wms2021.com.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow us on Twitter and LinkedIn.
Executive Director, Investor Relations
Head of Global Corporate Communications